nabumetone has been researched along with Aging in 4 studies
Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.
nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The most common adverse effects that occurred were related to the gastrointestinal tract, nervous system, skin, and special senses." | 6.67 | Clinical efficacy and safety of nabumetone in rheumatoid arthritis and osteoarthritis. ( Fleischmann, RM, 1992) |
| " The most common adverse effects that occurred were related to the gastrointestinal tract, nervous system, skin, and special senses." | 2.67 | Clinical efficacy and safety of nabumetone in rheumatoid arthritis and osteoarthritis. ( Fleischmann, RM, 1992) |
| "Nabumetone is a new, nonacidic, nonsteroidal antiinflammatory drug." | 2.38 | An overview of the clinical pharmacokinetics of nabumetone. ( Hyneck, ML, 1992) |
| "We have performed a detailed pharmacokinetic study of the plasma concentrations of the major active metabolite of nabumetone, 6-methoxy-2-naphthylacetic acid (6 MNA), attained after a single dose and during chronic administration comparing the results of a group of young healthy volunteers with those of a group of elderly arthritic patients." | 1.28 | A pharmacokinetic study of the active metabolite of nabumetone in young healthy subjects and older arthritis patients. ( Chellingsworth, MC; Jubb, R; Kendall, MJ; Kill, DC; Thawley, AR; Undre, NA, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hyneck, ML | 1 |
| Aronoff, GR | 1 |
| Fleischmann, RM | 1 |
| Kendall, MJ | 1 |
| Chellingsworth, MC | 1 |
| Jubb, R | 1 |
| Thawley, AR | 1 |
| Undre, NA | 1 |
| Kill, DC | 1 |
2 reviews available for nabumetone and Aging
| Article | Year |
|---|---|
An overview of the clinical pharmacokinetics of nabumetone.
Topics: Adult; Aged; Aging; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Eating; Humans; Ki | 1992 |
Therapeutic implications associated with renal studies of nabumetone.
Topics: Aging; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials as Topic; Double-Blind Me | 1992 |
1 trial available for nabumetone and Aging
| Article | Year |
|---|---|
Clinical efficacy and safety of nabumetone in rheumatoid arthritis and osteoarthritis.
Topics: Adult; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Butanon | 1992 |
1 other study available for nabumetone and Aging
| Article | Year |
|---|---|
A pharmacokinetic study of the active metabolite of nabumetone in young healthy subjects and older arthritis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Anti-Inflammatory Agents, Non-Steroidal; Arthriti | 1989 |